SpyGlass Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Cash & Equivalents	223.14	96.36	16.27
Short-Term Investments	11.04	11.08	-
Cash & Short-Term Investments	234.19	107.44	16.27
Cash Growth	-	560.41%	-
Other Receivables	0.68	0.43	0.42
Receivables	0.68	0.43	0.42
Prepaid Expenses	1.6	0.9	0.72
Total Current Assets	236.46	108.77	17.41
Property, Plant & Equipment	6.21	3.89	5.46
Long-Term Deferred Charges	-	2.72	-
Other Long-Term Assets	0.76	0.49	0.45
Total Assets	243.43	115.87	23.32
Accounts Payable	4.16	2.7	1.98
Accrued Expenses	1.72	2.18	1.28
Current Portion of Leases	-	-	0.44
Other Current Liabilities	3.56	3.71	4.09
Total Current Liabilities	9.44	8.58	7.79
Long-Term Leases	1.63	1.58	3.46
Total Liabilities	11.07	10.17	11.25
Additional Paid-In Capital	370.78	5.89	4.39
Retained Earnings	-138.41	-104.73	-64.86
Total Common Equity	232.36	-98.84	-60.47
Shareholders' Equity	232.36	105.7	12.07
Total Liabilities & Equity	243.43	115.87	23.32
Total Debt	1.63	1.58	3.9
Net Cash (Debt)	232.55	105.85	12.37
Net Cash Growth	-	755.66%	-
Net Cash Per Share	16.09	47.74	6.92
Filing Date Shares Outstanding	33.45	33.43	1.84
Total Common Shares Outstanding	33.45	2.2	1.84
Working Capital	227.02	100.18	9.62
Book Value Per Share	6.95	-44.85	-32.89
Tangible Book Value	232.36	-98.84	-60.47
Tangible Book Value Per Share	6.95	-44.85	-32.89
Machinery	2.89	2.3	1.99
Construction In Progress	2.98	0.43	-
Leasehold Improvements	0.58	0.62	0.62

SEC Filings: 10-K · 10-Q